These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32940635)

  • 41. Anti-A and SARS-CoV-2: an intriguing association.
    de Freitas Dutra V; Bonet-Bub C; Yokoyama APH; Achkar R; Machado RRG; Assunção M; Candelária G; Soares CP; Fachini RM; Fontão-Wendel R; Hamerschlak N; Reis LFL; Araujo DB; Nudelman V; Pinho JRR; Rizzo LV; Sakashita AM; Scuracchio P; Durigon EL; Wendel S; Kutner JM
    Vox Sang; 2021 May; 116(5):557-563. PubMed ID: 33650690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
    Zou J; Li L; Zheng P; Liang W; Hu S; Zhou S; Wang Y; Zhao J; Yuan D; Liu L; Wu D; Xu M; Zhang F; Zhu M; Wu Z; Cao X; Ni M; Ling X; Wu Y; Kuang Z; Hu M; Li J; Li X; Guo X; Xu T; Jiang H; Gao C; Yu M; Liu J; Zhong N; Zhou J; Huang JA; Jin T; He J
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35108220
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure.
    Keitel V; Bode JG; Feldt T; Walker A; Müller L; Kunstein A; Klindt C; Killer A; Senff T; Timm J; Ostermann P; Damagnez M; Lübke N; Adams O; Schaal H; Antoch G; Neubert J; Albrecht P; Meuth S; Elben S; Mohring A; Fischer JC; Bölke E; Hoenig M; Schulz AS; Luedde T; Jensen B
    Front Immunol; 2021; 12():645989. PubMed ID: 34012436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
    Vanhove B; Duvaux O; Rousse J; Royer PJ; Evanno G; Ciron C; Lheriteau E; Vacher L; Gervois N; Oger R; Jacques Y; Conchon S; Salama A; Duchi R; Lagutina I; Perota A; Delahaut P; Ledure M; Paulus M; So RT; Mok CK; Bruzzone R; Bouillet M; Brouard S; Cozzi E; Galli C; Blanchard D; Bach JM; Soulillou JP
    Eur J Immunol; 2021 Jun; 51(6):1412-1422. PubMed ID: 33576494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
    Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
    Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection.
    Orologas-Stavrou N; Politou M; Rousakis P; Kostopoulos IV; Ntanasis-Stathopoulos I; Jahaj E; Tsiligkeridou E; Gavriatopoulou M; Kastritis E; Kotanidou A; Dimopoulos MA; Tsitsilonis OE; Terpos E
    Viruses; 2020 Dec; 13(1):. PubMed ID: 33375675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
    Raturi M; Kusum A; Kala M; Mittal G; Sharma A; Bansal N
    Transfus Clin Biol; 2021 Aug; 28(3):300-302. PubMed ID: 33971318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening.
    Zilla M; Wheeler BJ; Keetch C; Mitchell G; McBreen J; Wells A; Shurin MR; Peck-Palmer O; Wheeler SE
    Am J Clin Pathol; 2021 Feb; 155(3):343-353. PubMed ID: 33155015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.
    Bansal N; Raturi M; Bansal Y
    Transfus Clin Biol; 2021 Aug; 28(3):308-309. PubMed ID: 33971319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Upper age limits for convalescent plasma donation and treatment of COVID-19 patients: A further marker of ageism.
    Fedecostante M; O'Neill D; Pierri F; Carrieri B; Lattanzio F; Cherubini A
    Transfusion; 2021 Sep; 61(9):2799-2800. PubMed ID: 34227110
    [No Abstract]   [Full Text] [Related]  

  • 52. The need for and challenges of comparing SARS-CoV-2 antibody assays.
    Jacquot C; Feys HB
    Transfus Med; 2021 Jun; 31(3):147-148. PubMed ID: 34110048
    [No Abstract]   [Full Text] [Related]  

  • 53. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran.
    Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M
    Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma.
    Tonn T; Corman VM; Johnsen M; Richter A; Rodionov RN; Drosten C; Bornstein SR
    Lancet Microbe; 2020 Jun; 1(2):e63. PubMed ID: 32835332
    [No Abstract]   [Full Text] [Related]  

  • 55. Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland.
    Kasztelewicz B; Janiszewska K; Burzyńska J; Szydłowska E; Migdał M; Dzierżanowska-Fangrat K
    PLoS One; 2021; 16(4):e0249550. PubMed ID: 33793673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recommendations on the use of COVID-19 Convalescent Plasma to Treat Immunocompromised Patients.
    Franchini M; Casadevall A; Senefeld JW; Joyner MJ; Sullivan DJ; Focosi D
    Semin Thromb Hemost; 2024 Jun; 50(4):648-653. PubMed ID: 37984358
    [No Abstract]   [Full Text] [Related]  

  • 57. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.
    Kataria Y; Cole M; Duffy E; de la Cena K; Schechter-Perkins EM; Bouton TC; Werler MM; Pierre C; Ragan EJ; Weber SE; Jacobson KR; Andry C
    Sci Rep; 2021 May; 11(1):9694. PubMed ID: 33958668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis.
    Galanis P; Vraka I; Fragkou D; Bilali A; Kaitelidou D
    J Hosp Infect; 2021 Feb; 108():120-134. PubMed ID: 33212126
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Re: "Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2" by Krsak
    Mishra BK; Bhattacharya D; Kshatri JS; Pati S
    Viral Immunol; 2021 Nov; 34(9):658. PubMed ID: 34672807
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.